secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001193125-22-190873
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics reports positive Phase 2a data for PLN-74809 in IPF; FVC and QLF improved
--------------------------------------------------------------------------------

- INTEGRIS-IPF Phase 2a met primary and secondary endpoints; PLN-74809 well tolerated with no drug-related SAEs or discontinuations.
- Pooled PLN-74809 showed 80% reduction in FVC decline vs placebo (-15.1 mL vs -74.1 mL); 80 mg dose showed +24.6 mL FVC increase from baseline.
- Dose-dependent reduction in ≥10% FVCpp decline: 18.2% (40mg), 8.7% (80mg), 4.5% (160mg) vs 17.4% placebo.
- QLF imaging showed dose-dependent antifibrotic effect; 160 mg group showed 0.00% mean change vs 1.15% placebo.
- Company to discuss data with regulators; 320 mg cohort data expected early 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/0001193125-22-190873-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312522190873/d356984d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-190873

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer